TY  - JOUR
AU  - Van De Sande, Michiel
AU  - Tap, William D
AU  - Gelhorn, Heather L
AU  - Ye, Xin
AU  - Speck, Rebecca M
AU  - Palmerini, Emanuela
AU  - Stacchiotti, Silvia
AU  - Desai, Jayesh
AU  - Wagner, Andrew J
AU  - Alcindor, Thierry
AU  - Ganjoo, Kristen
AU  - Martín-Broto, Javier
AU  - Wang, Qiang
AU  - Shuster, Dale
AU  - Gelderblom, Hans
AU  - Healey, John H
PY  - 2021
DO  - 10.1080/17453674.2021.1922161
UR  - http://hdl.handle.net/10668/17780
T2  - Acta orthopaedica
AB  - Background and purpose - The ENLIVEN trial showed that, after 25 weeks, pexidartinib statistically significantly reduced tumor size more than placebo in patients with symptomatic, advanced tenosynovial giant cell tumor (TGCT) for whom surgery was not...
LA  - en
KW  - Adult
KW  - Aminopyridines
KW  - Double-Blind Method
KW  - Female
KW  - Giant Cell Tumor of Tendon Sheath
KW  - Humans
KW  - Lower Extremity
KW  - Male
KW  - Middle Aged
KW  - Patient Reported Outcome Measures
KW  - Pyrroles
TI  - Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial.
TY  - research article
VL  - 92
ER  -